3-Iodobenzylguanidine

• 

  Subject Areas on Research

  • (4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography. 
  • 1-(m-[211At]astatobenzyl)guanidine: synthesis via astato demetalation and preliminary in vitro and in vivo evaluation. 
  • 3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells. 
  • A 4-methyl-substituted meta-iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells. 
  • A kit method for the high level synthesis of [211At]MABG. 
  • A radioiodinated MIBG-octreotate conjugate exhibiting enhanced uptake and retention in SSTR2-expressing tumor cells. 
  • Abnormalities of cardiac sympathetic function in pacing-induced heart failure as assessed by [123I]metaiodobenzylguanidine scintigraphy. 
  • Biological evaluation of ring- and side-chain-substituted m-iodobenzylguanidine analogues. 
  • Carcinoid tumors: iodine-131 MIBG scintigraphy. 
  • Carrier-free 131I-meta-iodobenzylguanidine: comparison of production from meta-diazobenzylguanidine and from meta-trimethylsilylbenzylguanidine. 
  • Catabolism of 4-fluoro-3-iodobenzylguanidine and meta-iodobenzylguanidine by SK-N-SH neuroblastoma cells. 
  • Comparison of radiohaloanalogues of meta-iodobenzylguanidine (MIBG) for a combined gene- and targeted radiotherapy approach to bladder carcinoma. 
  • Comparison of ¹²³I-metaiodobenzylguanidine (MIBG) and ¹³¹I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. 
  • Detecting pheochromocytoma: defining the most sensitive test. 
  • Effect of mild hyperglycemia +/- meta-iodo-benzylguanidine on the radiation response of R3230 Ac tumors. 
  • Effects of specific activity on meta-[(131)I]iodobenzylguanidine kinetics in isolated rat heart. 
  • Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I]meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma. 
  • Evaluation of meta-[211At]astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft model. 
  • Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. 
  • Factors controlling oxygen utilization. 
  • Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. 
  • Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. 
  • Iodine 131-labeled metaiodobenzylguanidine scintigraphy and biochemical analyses in suspected pheochromocytoma. 
  • Iodine-123-4-amino-3-iodobenzylguanidine, a new sympathoadrenal imaging agent: comparison with iodine-123 metaiodobenzylguanidine. 
  • Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients. 
  • Iodine-131-metaiodobenzylguanidine uptake in metastatic carcinoid tumor to the orbit. 
  • Iodopyridine-for-iodobenzene substitution for use with low molecular weight radiopharmaceuticals: application to m-iodobenzylguanidine. 
  • Localisation of [131I]MIBG in nude mice bearing SK-N-SH human neuroblastoma xenografts: effect of specific activity. 
  • MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. 
  • MIBG inhibits respiration: potential for radio- and hyperthermic sensitization. 
  • MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis. 
  • Meta-[131I]iodobenzylguanidine uptake and meta-[211At]astatobenzylguanidine treatment in human medulloblastoma cell lines. 
  • Meta-[211At]astatobenzylguanidine: further evaluation of a potential therapeutic agent. 
  • Meta-iodobenzylguanidine and analogues: chemistry and biology. 
  • Meta-iodobenzylguanidine derivatives containing a second guanidine moiety. 
  • Metaiodobenzylguanidine imaging in diabetes mellitus: assessment of cardiac sympathetic denervation and its relation to autonomic dysfunction and silent myocardial ischemia. 
  • New MIBG preparation to improve targeted radiotherapy and reduce toxic side-effects in neuroblastoma patients undergoing combination treatment. 
  • No-carrier-added iodine-131-FIBG: evaluation of an MIBG analog. 
  • No-carrier-added meta-[123I]iodobenzylguanidine: synthesis and preliminary evaluation. 
  • No-carrier-added synthesis of a 4-methyl-substituted meta-iodobenzylguanidine analogue. 
  • No-carrier-added synthesis of meta-[131I]iodobenzylguanidine. 
  • Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. 
  • Phase-1 clinical trial results of high-specific-activity carrier-free 123I-iobenguane. 
  • Pheochromocytoma and functional paraganglioma. 
  • Radiation dosimetry, pharmacokinetics, and safety of ultratrace Iobenguane I-131 in patients with malignant pheochromocytoma/paraganglioma or metastatic carcinoid. 
  • Radioiodinated O(6)-Benzylguanine derivatives containing an azido function. 
  • Radioiodinated metaiodobenzylguanidine in the diagnosis and therapy of carcinoid tumors. 
  • Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group. 
  • Synthesis and evaluation of 4-[18F]fluoropropoxy-3-iodobenzylguanidine ([18F]FPOIBG): A novel 18F-labeled analogue of MIBG. 
  • Synthesis of carrier-free 131I-meta-iodobenzyl-guanidine by novel routes to enhance therapeutic efficiency in neuroblastoma. 
  • Synthesis of ring- and side-chain-substituted m-iodobenzylguanidine analogues. 
  • Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions. 
  • Uptake mechanisms of meta-[123I]iodobenzylguanidine in isolated rat heart. 
  • Validation of 4-[fluorine-18]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG. 
  • Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1. 
  • Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials. 
  • Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group.